Sanctuary Advisors LLC boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 82.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,444 shares of the biotechnology company's stock after buying an additional 32,183 shares during the period. Sanctuary Advisors LLC's holdings in Exelixis were worth $2,353,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FMR LLC increased its position in Exelixis by 6.1% during the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock valued at $63,891,000 after buying an additional 140,568 shares in the last quarter. Los Angeles Capital Management LLC increased its position in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company's stock valued at $46,473,000 after buying an additional 991,494 shares in the last quarter. Two Sigma Advisers LP increased its position in Exelixis by 6.1% during the 3rd quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company's stock valued at $44,182,000 after buying an additional 98,000 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after buying an additional 704,786 shares in the last quarter. Finally, Systematic Financial Management LP increased its position in Exelixis by 7.1% during the 3rd quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company's stock valued at $30,320,000 after buying an additional 77,599 shares in the last quarter. Institutional investors own 85.27% of the company's stock.
Shares of Exelixis stock opened at $36.85 on Friday. Exelixis, Inc. has a one year low of $20.14 and a one year high of $37.59. The stock's fifty day moving average is $34.20 and its 200 day moving average is $31.28. The stock has a market cap of $10.31 billion, a P/E ratio of 20.82, a P/E/G ratio of 1.13 and a beta of 0.53.
Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.
A number of research analysts recently weighed in on the company. Piper Sandler raised their price objective on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Morgan Stanley upgraded Exelixis from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $30.00 to $40.00 in a research note on Monday, January 27th. Oppenheimer downgraded Exelixis from an "outperform" rating to a "market perform" rating and cut their target price for the company from $41.00 to $33.00 in a research note on Friday, January 24th. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Exelixis in a research note on Thursday, February 13th. Finally, Wells Fargo & Company increased their target price on Exelixis from $32.00 to $36.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $37.24.
Check Out Our Latest Stock Report on Exelixis
In other Exelixis news, EVP Jeffrey Hessekiel sold 60,000 shares of the firm's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now directly owns 486,059 shares of the company's stock, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.85% of the stock is owned by insiders.
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Exelixis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.
While Exelixis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.